Ribo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillation

April 14 – Suzhou, China and Mölndal, Sweden Suzhou Ribo Life Science (6938.HK) and its subsidiary Ribocure Pharmaceuticals AB, (together “Ribo”) today announced the successful submission of a Phase 2b Clinical Trial Application (CTA) to the European Medicine Agency (EMA) for vortosiran (RBD4059), the world’s first and most advanced siRNA therapy targeting Factor XI (FXI), for stroke prevention […]
Ribo Appoints CMO and CBO to Empower Global R&D and Partnerships

March 26, 2026 – Suzhou Ribo Life Science Co., Ltd. (“Ribo” or “the Company”, Hong Kong Stock Exchange code: 6938) today announced two key executive appointments, as approved by the Board of Directors; Dr. Anders Gabrielsen, former Vice President and Global Head of Clinical Development, has been appointed Chief Medical Officer (CMO), and will oversee […]
Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

Suzhou Ribo Life Science Co., Ltd. (“Ribo” or “the Company”, Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences. Following Ribo’s success of the RiboGalSTAR™ targeting liver specific genes with seven programs in […]
Ribo and Ribocure Announce Exclusive Global Licensing Agreement

Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) (“Ribo”) and its subsidiary Ribocure Pharmaceuticals AB (“Ribocure”) today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize […]
Recent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapy

Recent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapy Recent advances in factor XI (FXI) inhibition continue to reshape the landscape of anticoagulation therapy and thrombosis prevention. We acknowledge the positive results from the phase III OCEANIC-STROKE study of asundexian in secondary stroke prevention, demonstrating that FXI inhibition can significantly […]
Ribo is Advancing Kidney-Targeted Therapeutics

We recently presented a poster at the ASN Kidney Week in Texas, showcasing the kidney-targeted delivery of siRNA using our RIBO-PepSTAR™ peptide conjugates. This work highlights the growing validation of Ribos Renal platform – designed to silence the right target in the right cell type, specifically in the kidney. By enabling precise delivery of small interfering RNAs to the kidney, […]
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

BEIJING, China & GOTHENBURG, Sweden — 2025-10-24 — Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection. The EMA’s ODD is assigned to investigational therapies of life-threatening or […]
Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies

SuZhou Ribo life science Ltd. Co. and Ribocure Pharmaceuticals AB (Ribo) presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline. Ribo presented results from its ApoC3-silencing RBD5044 program`s Phase 1 clinical trial, which included single and multiple ascending dose studies (n=72 healthy […]
Distinguished Swedish Investors Back Leading Biotech Company in GoCo Health Innovation City to Advance siRNA Therapies

Mölndal, July 2nd 2025 — We are delighted to announce that distinguished Swedish investors Erik Selin and Jacob Torell have joined Ribocure as new shareholders. Through a direct investment totaling USD 33 million, Erik Selin now holds 32.65% of Ribocure shares, while Jacob Torell holds 1%. We thereby warmly welcome Erik Selin as a new […]
Ribocure Pharmaceuticals represented at European Liver Congress, EASL, in Vienna

Li-ming Gan, CEO at Ribocure Pharmaceuticals, is for the first time showing our preclinical PoC data at the EASL meeting this week. The study was conducted using our mouse surrogate molecule in an in-house developed mouse model of NASH with elevated hepatic HSD expression. HSD17B13 is a genetically identified target strongly associated with liver steatosis […]